Nearly half of Israel’s population gets Pfizer-BioNTech vaccine: Preventing deaths from COVID-19 is up to 99% effective

The research and development of vaccines that help prevent and limit the spread of COVID-19 has been one of the most important problems in many countries around the world. However, for a vaccine to be produced and consumed in large quantities, and at the same time, ensuring the health of the people is not easy.

Since June 2020, the Advisory Committee on Immunization Practices (ACIP) – a Commission under the US Centers for Disease Control and Prevention, has convened nine public meetings to review the data. in relation to COVID-19 epidemiology and possible use of COVID-19 vaccine.

In it, they used the EtR framework to measure and evaluate in detail the benefits and harms of vaccines under the supervision and participation of infectious disease experts. vaccination, vaccine safety, public health and ethics. After systematically reviewing the literature, the research teams evaluated the efficacy of a vaccine called Pfizer-BioNTech COVID-19.

At that time, the evidence base for the Pfizer-BioNTech COVID-19 vaccine was primarily reported by a large clinical trial with more than 43,000 subjects randomly selected to participate. This includes people aged 16-91 years old.

Through clinical trial, the findings have proven the vaccine’s efficacy to be up to 95% in preventing COVID-19. This is the most effective vaccine observed in age groups, sex, race, ethnicity, and in people with an underlying medical condition. According to the ACIP, vaccination with the Pfizer-BioNTech COVID-19 vaccine will consist of 2 doses (30 μg, 0.3 mL each), administered in the biceps. Each shot is 3 weeks apart, equivalent to 21 days.

After collecting the positive results, on December 11, 2020, the Food and Drug Administration under the sections of the U.S. Food and Drug Act granted the first emergency use license. (EUA) for the Pfizer-BioNTech COVID-19 vaccine distributed in the United States. In addition, on 12/12/2020, in order to ensure the safety of health, ACIP also issued a temporary recommendation for the use of Pfizer-BioNTech COVID-19 vaccine for those who equal, above 16 years old for COVID-19 prevention.

Thereby, when confirming the effectiveness of the Pfizer-BioNTech COVID-19 vaccine in the United States, Israel implemented the vaccine program Pfizer-BioNTech COVID-19 and achieved many positive results. in the country.

Beginning of the vaccination program on December 20, Israel has increased the effectiveness of the Pfizer-BioNTech COVID-19 vaccine by 89.4% in preventing the disease in the early stages. Israel companies and the Ministry of Health have also worked together on preliminary observational analysis.

Up to now, according to reports from Israeli researchers, the Pfizer-BioNTech vaccine has helped prevent the COVID-19 infection in this country. This result is also reported on the website Der Spiegel, showing the sensitivity and effectiveness of the Israeli government in researching and deploying this vaccine to the people.

Even nearly half of the population has received at least one dose of the vaccine. “Currently, the Pfizer-BioNTech COVID-19 vaccine is 99% effective in preventing death from the virus,” the Israeli authorities said.

As of February 6, about 27% of people 15 years of age and older in Israel were fully vaccinated with the Pfizer-BioNTech vaccine. In order to verify side effects and unusual symptoms, people will be re-examined 7 days after the second dose.

However, according to previous ACIP research, people who have tested the vaccine often have no strange reactions, or only mild to moderate reactions. For other unusual reactions, usually detected in the first injection within 1-2 days after injection will be tested and treated promptly.

Pfizer and BioNTech – two companies coordinating, producing vaccines Pfizer-BioNTech COVID-19 said they are analyzing data from Israel to check the accuracy of the effectiveness of the vaccine on the population. . This data will be shared as soon as it is completed.

Although there is still a lot of concern surrounding the COVID-19 preventive vaccine, the Pfizer-BioNTech COVID-19 vaccine also has a good start, which has great significance in current vaccine research. . Thereby, to develop and widely disseminate Pfizer-BioNTech COVID-19 vaccine, the vaccine needs to be verified in the coming time to demonstrate its strength in the market and continue to prioritize the innovation to bring all kinds of healthy health in the prevention and prevention of disease.